Development and validation of non-invasive models in predicting advanced fibrosis of choledochal cyst

Abstract

Abstract

Purpose

Patients with choledochal cyst (CDC) develop liver fibrosis, especially advanced fibrosis without prompt surgery. This study validated the aspartate aminotransferase (AST)-to-platelet ratio index (APRI) and Fibrosis-4 index (FIB-4) and constructed a model for predicting advanced fibrosis in pediatric CDCs.

Methods

Between January 2020 and March 2022, 330 CDCs (advanced fibrosis: 34, Ludwig staging 3–4; non-advanced fibrosis: 296, Ludwig staging 0–2) were reviewed. APRI and FIB-4 were validated. The area under the receiver operating characteristic (AUROC) curve was used to assess discrimination. Relevant variables were analyzed by backward stepwise logistic regression. Enhanced bootstrap method was used for internal verification with 1000 samples.

Results

The AUROCs of APRI and FIB-4 were 0.761 (0.673–0.850) and 0.561 (0.455–0.667). AST to prealbumin ratio (APAR), was constructed with an AUROC of 0.776 (0.693–0.860). The AUROCs of APAR + APRI and APAR + FIB-4 were 0.791 (0.713–0.869) and 0.782 (0.699–0.865). No significant differences were noted in the AUROCs of the indices or their combinations. APAR and APRI could be used together to reduce missed diagnosis rate. The risk of advanced fibrosis varied from different APAR and APRI scores.

Conclusion

Both APAR and APRI were indispensable to identify CDC patients at high risk of advanced fibrosis.

Keywords

Hashtags

This article is published on an external journal. Click below to read the full text.